Topical dsRNA challenges may induce overexpression of airway antiviral cytokines in symptomatic allergic disease. A pilot in vivo study in nasal airways  by Brandelius, Angelica et al.
Respiratory Medicine (2014) 108, 1816e1819Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate /rmedSHORT COMMUNICATIONTopical dsRNA challenges may induce
overexpression of airway antiviral cytokines
in symptomatic allergic disease. A pilot
in vivo study in nasal airways
Angelica Brandelius a, Morgan Andersson b, Lena Uller a,*a Unit of Respiratory Immunopharmacology, Dept. Experimental Medical Science, Lund University,
Sweden
b ENT Lund University Hospital, SwedenReceived 14 July 2014; accepted 17 October 2014
Available online 25 October 2014KEYWORDS
Asthma;
Allergy;
Rhinitis;
Asthma exacerbation;
Epithelial cells;
TLR3* Corresponding author. Dept. Exper
Lund, Sweden. Tel.: þ46 46 2220413.
E-mail address: lena.uller@med.lu
http://dx.doi.org/10.1016/j.rmed.20
0954-6111/ª 2014 Elsevier Ltd. All rigSummary
Background: Airway challenge with dsRNA is of interest since this agent acts on TLR3 and
mimics rhinoviral (RV) infection-induced interferons/cytokines. Contrasting frequent employ-
ment of dsRNA in epithelial cell cultures there is no information on effects of dsRNA adminis-
tered to human airways in vivo. Here we explore effects of nasal dsRNA challenges in subjects
with seasonal allergic rhinitis inside and outside Swedish birch pollen season.
Methods: We examined effects of dsRNA in seven patients with seasonal allergic rhinitis. By
being studied both inside and outside of an active pollen season they served as their own con-
trols. Based on pilot experiments a repeat dose regimen of dsRNA, 4  100 mg, was given daily
into the right nostril on two consecutive days; left nostril received corresponding saline chal-
lenges. Airway cells for gene analyses were obtained by nasal brushing shortly before the first
challenge and 48 h after challenges.
Results: Pollen counts and nasal symptoms indicated a significant season of allergic rhinitis. At
the height of the pollen season, dsRNA challenges increased three antiviral proteins, inter-
ferons b and l1 and IL-32, compared to saline challenges. By contrast, outside the pollen sea-
son dsRNA did not increase the expression of these antiviral proteins. dsRNA did not cause any
symptoms outside the season nor did it increase the allergic symptoms evoked by natural pol-
len exposure.imental Medical Science, Unit of Respiratory Immunopharmacology, BMC D12, Lund University, 221 84
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siveness of airway surface cells.
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Cellular studies indicate that TLR3 recognizes viral dsRNA
and its synthetic analogue poly(I:C). Thus, dsRNA induces
interferons (IFNs) and cytokines/chemokines in airway
epithelial cell cultures [1e3]. In vivo in mice local airway
dsRNA challenges increase lung expression of IFNl only
when superimposed on established allergic inflammation
[4]. We speculated that an ongoing allergic inflammation
may make airways more prone to produce antiviral pro-
teins. This possibility would actually agree with previous
observations in rhinitis and asthma patients where allergen
challenges, surprisingly, have reduced inflammatory and
clinical effects of viral inoculation [5,6].
Subcutaneous dsRNA in humans produces blood cell
expression of IFNs similar to effects of live virus [7]. However,
contrasting the ubiquitous use of dsRNA in cell cultures and
animal models, there are no known reports of dsRNA-induced
effects in vivo in human airways. Here we examine effects on
human nasal mucosa in vivo of sub-symptomatic dsRNA chal-
lenges.We report on expression of IFNb and IFNl1, two central
IFNs in bronchial epithelial antiviral responses in asthma
(reviewed in [8]), and IL-32, a cytokine with antiviral proper-
ties that additionally may induce IFNl1 expression [9].
Material and methods
Subjects
Nine subjects meeting the inclusion criteria that included
strict seasonal allergic rhinitis (AR) were recruited; two
withdrew due to intolerable allergic symptoms during the
studied season. Seven subjects with AR to birch pollen (skin
prick tests and history) participated (six males, aged 23e39
years). They had normal ear-, nose- and throat. Persistent
AR, chronic rhinosinusitis, nasal polyposis or other struc-
tural abnormalities, asthma, airway infection within 14
days before the first visit, were exclusion criteria. All were
free of corticosteroids 4 weeks and antihistamines 2 days
prior to the study. None was positive for house dust mite
but six positive for timothy grass. Four subjects were pos-
itive but not exposed to cat and/or dog dander. The study
was conducted according to the declaration of Helsinki and
approved by the Institutional Review Board of Lund Uni-
versity (Dnr 2011/218). All patients provided written
informed consent. Pollen was counted (Burkard pollen trap
situated 20 km from the study centre).
dsRNA administration
Preliminary experiments indicated that doses of 100 mg of
dsRNA were well tolerated. 100 ml sterile endotoxin-freephysiologic saline solution (NaCl, 0.9%) containing dsRNA
(1 mg/ml) (Invivogen, San Diego, California) was adminis-
tered with a pipette on the inferior turbinate in the right
nostril 4 times with 15 min interval day 1 and day 2. The left
nostril received corresponding physiologic saline solutions.
Nasal brushings
Prior to each brushing, nasal lavage with 10 ml physiological
saline solution, administered with a pipette tip to each
nostril, washed out decay products. Then nasal brushings
for gene expression analyses were obtained before dsRNA-
administration day 1 and day 3 (48 h after start of dsRNA-
administrations). Nasal brushing was performed with an
interdental brush (Apoteket AB, Sweden) between the
inferior turbinate and septum in both nostrils [10].
Total nasal symptom score
Each patient was provided with a diary card on which nasal
symptoms were recorded twice a day, one week before and
during the study with the dsRNA provocation using an
arbitrary four-step scale from 0 to 3 (0 e no; 1 e mild; 2 e
moderate; 3 e severe symptoms). The sum of the nasal
symptoms (itching/sneezing, secretion and blockage) was
added to a total nasal symptom score, which could maxi-
mally reach 9.
Gene expression analysis in nasal brushings
Nasal brushing material was treated with lysis buffer from
RNA isolation kit (Nucleospin RNA XS kit, Macherey-Nagel,
Du¨ren, Germany) and stored in 80 C until further RNA
extraction. Total RNA was extracted from the brushing
samples using the mentioned kit according to the manu-
facturer’s instructions. 1 mg of RNA was reverse transcribed
to cDNA (Precision nanoscript Reverse Transcription Kit,
Primerdesign). Briefly, thermocycling and real-time detec-
tion of PCR products were performed on an IcyclerIQ
sequence detection system (Stratagene, Mx3000P, La Jolla,
Calif., USA) with standard cycling parameters. Genes of
interest were normalized to the geometric means of
reference genes Ubiquitin C (UBC) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) using the delta-Ct
method. Within-subject comparisons were normalized to
one control sample (the left base-line nostril at time-point
0) using the delta-delta Ct-method. The following primer
sequences were used for IFN-b, IFN-l1 (interleukin 29) and
IL-32, transcript variant 1. IFN-b: TTACTTCATTAACA-
GACTTACAGGT (forward) and TACATTAGCCATCAGTCACT-
TAAAC (reverse). IFN-l1: ATGGGAACCTGTGTCTGAGAA
(forward) and GGGTGAGAGGAAATAAATTAAGGAA (reverse).
Figure 1 Local birch pollen counts and daily mean total nasal symptoms scores (TNSS) during (a) the pollen season. Arrows
indicate start and end of the dsRNA-challenges and sampling periods. TNSS were increased during the active pollen season (a)
compared with outside (b) the season, p < 0.0001. Moreover, the present dsRNA-challenges were without effects on symptoms both
during (a) and outside (b) the pollen season. Gene expression of 3 antiviral cytokines in nasal epithelial brushings is shown (ceh).
Nasal saline challenges did not increase gene expression (from baseline, at 0 h, to post challenge, at 48 h, in the left nostril). During
(c,e,g) but not outside (d,f,h) the pollen season, dsRNA challenges induced gene expression of IFNb (c), IFNl1 (e) and IL32 (g)
(*p < 0.05, **p < 0.01: baseline compared to post challenge). Data are presented as median  IQR.
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(forward) and GATTGGGGTTCAGAGCACTTC (reverse).
Statistical analysis
Statistical analysis was performed using the software
Graph-Pad Prism version 5.0c (GraphPad Software, San
Diego, Calif., USA). Data regarding TNSS are presented as
mean values. When comparing TNSS during and outside
birch pollen season the data were analysed using Krus-
kaleWallis test. Regarding the antiviral cytokines, the data
are presented as median with interquartile range and all
data were analysed using non-parametric tests. Compari-
sons between time-points in each nasal cavity were ana-
lysed using Wilcoxon matched-pairs signed rank test. p-
values <0.05 were considered statistically significant.
Results and discussion
Total nasal symptom score and pollen counts indicated a
significant pollen season especially during the period when
dsRNA challenges were carried out (Fig. 1a and b).
Reflecting threshold dose levels, dsRNA challenges did not
produce symptoms (Fig. 1a and b) nor increase expression
of a Th2-type hub cytokine like TSLP [3] (data not shown).
Notably, at the height of pollen season dsRNA increased
IFNb (p < 0.05), IFNl1 (p < 0.01), and IL-32 (p < 0.05)
compared to saline control (Fig. 1)ceh. Hence, the topi-
cally administered viral infection mimic increased
expression of antiviral proteins in human allergic nasal
airways during an active symptomatic allergic season, but
not outside the season when there were no signs of
allergic disease. The positive responses may not reflect
increased penetration of topical dsRNA because the
allergic season is rather associated with reduced absorp-
tion permeability [11].
Our findings are novel but need confirmation by further
studies involving larger numbers of patients as well as
extending the approach to include bronchial challenges and
sampling. The present data are of interest because they
suggest the possibility that patients with established
symptomatic allergic processes in the airway mucosa may
not be as vulnerable to additional viral infections as atopic
individuals without allergic symptoms. This notion is sup-
ported by previous observations in rhinitis and asthma pa-
tients where allergen challenges actually reduced
inflammatory and clinical effects of inoculation with
rhinovirus [5,6]. The present data and the unexpected ob-
servations in viral inoculation studies [5,6] might well be
compatible with the acknowledged risk that, once infec-
ted, patients with asthma may react with severe exacer-
bations of their disease.
We employed doses of dsRNA that were below threshold
regarding symptoms. Future work may explore extended
challenges with dsRNA aiming to mimic RV infection more
fully. This is warranted because dsRNA challenges would
have advantages over RV inoculation studies including in-
dependence of variable infection intensities and take rates.
Future studies are further warranted to further explore
mechanisms of allergic disease processes that interact with
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